Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Sales (2016 - 2025)

Historic Return on Sales for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 0.08%.

  • NovaBay Pharmaceuticals' Return on Sales rose 4400.0% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.09%, marking a year-over-year increase of 2700.0%. This contributed to the annual value of 0.01% for FY2024, which is 3600.0% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Return on Sales stood at 0.08% for Q3 2025, which was up 4400.0% from 0.03% recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Return on Sales high stood at 0.08% for Q3 2025, and its period low was 2.25% during Q4 2022.
  • For the 5-year period, NovaBay Pharmaceuticals' Return on Sales averaged around 0.44%, with its median value being 0.16% (2023).
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Return on Sales plummeted by -22000bps in 2022 and then soared by 12300bps in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Return on Sales (Quarter) stood at 0.05% in 2021, then tumbled by -4424bps to 2.25% in 2022, then surged by 41bps to 1.33% in 2023, then soared by 93bps to 0.1% in 2024, then soared by 178bps to 0.08% in 2025.
  • Its Return on Sales stands at 0.08% for Q3 2025, versus 0.03% for Q2 2025 and 0.03% for Q1 2025.